Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743725 | 0.95 | KDM4E (0.50) | KDM4EPKMHSD17B10HRH4HTR3A | |
| SCHEMBL6489767 | 0.87 | HRH4 (0.42) | KDM4EPKMHSD17B10HRH4HTR3A | |
| SCHEMBL6010776 | 0.85 | NUDT1 (0.49) | KDM4EHRH4HTR3AMETKMT2A | |
| SCHEMBL6010856 | 0.84 | PDE10A (0.44) | HRH4HTR3A | |
| Hydrochloric Acid SCHEMBL7244790 | 0.84 | HRH4 (0.42) | KDM4EPKMHSD17B10HRH4HTR3A | |
| SCHEMBL5021460 | 0.84 | PTGES (0.37) | KDM4EPKMHSD17B10 | |
| Hydrochloric Acid SCHEMBL6010724 | 0.83 | PDE10A (0.43) | HRH4HTR3A | |
| SCHEMBL7244793 | 0.83 | HRH4 (0.40) | KDM4EPKMHSD17B10HRH4HTR3A | |
| SCHEMBL6489109 | 0.81 | NUDT1 (0.44) | KDM4EPKMHSD17B10HRH4HTR3A | |
| SCHEMBL6486107 | 0.81 | NUDT1 (0.44) | KDM4EPKMHSD17B10HRH4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045516-B1 | Benzoxazole derivatives and drugs containing the same as the active ingredient | KOICHI SHUDO (JP) | 2006-05-16 | — | — | US | disclosed |
| US-6867226-B2 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1134220-B1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | SHUDO KOICHI (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6552057-B2 | In addition to 5-HT3 receptor antagonism, and inhibiting diarrhea without causing constipation as side effect; benzoxazole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0806419-B1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. | 2003-01-16 | — | — | US | disclosed |
| US-6333328-B1 | MIXING BENZOXAZOLE DERIVATIVE WITH CARRIER TO FORM ACTIVATOR COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6297246-B1 | BENZOXAZOLE DERIVATIVES; DOES NOT CAUSE CONSTIPATION AS A SIDE EFFECT. | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-1134220-A1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6037342-A | BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS | MEIJI SEIKA KAISHA, LTD (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0806419-A1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | HTR7, HTR1A, HTR3A | KDM4E 1908/4885PKM 2998/4885HSD17B10 3471/4885 |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | HTR7, HTR3A, HTR1A | KDM4E 2012/4885PKM 2994/4885HSD17B10 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.